Integrated Diagnostics Holdings Plc

Integrated Diagnostics Holdings Plc

0.49
USD
-0.01
(-2.00%)
0.03EPS
10.80P/E
183.90MMarket Cap
Nov 12Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.12
1.43
1.69
1.95
2.52
3.2
3.71
4.43
8.71
6.01
6.87
9.64
13.51
7.91
Basic EPS, GAAP
0.1
0.22
0.24
0.43
0.62
0.84
0.85
0.99
2.35
0.9
0.85
1.82
2.17
1.36
Free Cash Flow per Basic Share
0.31
0.38
0.22
0.58
0.41
0.37
0.8
1.26
3.34
-0.17
0.36
2.26
2.38
1.01
Dividend per Share
0.45
0.39
0.01
0.15
0.63
0.72
0.75
0.75
0.8
2.35
- -
0.05
0.92
- -
Book Value per Share
3.18
2.94
3.16
3.73
3.74
3.78
3.69
3.78
4.3
3.59
4.46
4.66
5.82
4.64
Tangible Book Value per Share
0.35
0.26
0.48
0.97
0.98
1
0.92
1.02
1.54
0.75
1.61
1.56
2.63
1.67
Basic Weighted Avg Shares
600
600
600
600
600
600
600
600
600
600
600
594
581
600
Sales/Revenue/Turnover
672
860
1,015
1,171
1,514
1,921
2,226
2,656
5,225
3,605
4,123
5,720
7,855
4,748
Operating Margin (%)
20.88
30.14
27.91
40.09
36.05
36.15
35.91
38.69
43.77
24.21
19.17
21.22
27.05
20.08
Depreciation Expense
145
116
36
45
62
77
153
185
239
317
401
483
565
438
Net Income, GAAP
62
133
145
260
374
502
511
594
1,413
541
510
1,077
1,262
817
Effective Tax Rate (%)
50.6
42.7
43.54
31.3
31.28
30.73
33.45
37.11
33.14
38.31
36.48
29.95
38.56
33.88
Profit Margin (%)
9.25
15.43
14.28
22.24
24.7
26.13
22.95
22.36
27.04
15.01
12.38
18.84
16.07
17.21
Working Capital
188
129
198
498
494
386
210
351
694
160
687
916
1,254
1,010
LT Debt
1
1
60
120
139
167
358
466
722
1,008
959
1,011
1,195
1,013
Total Equity
1,946
1,805
1,942
2,299
2,314
2,401
2,360
2,426
2,794
2,447
3,101
3,499
4,130
3,552
Return on Invested Capital (%)
3.18
7.29
7.49
13.69
14.37
17.61
18.21
20.16
41.88
13.32
11.95
18.26
23.95
14.92
Return on Capital (%)
2.76
6.61
7.22
11.65
15.05
20.2
20.58
21.48
42.17
17.35
16.25
27.37
25.21
25.59
Return on Common Equity (%)
3.15
7.23
7.92
12.6
16.69
22.24
22.78
26.49
58.22
22.85
21.12
39.99
41.43
31.08

Capital Structure

EGP

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
220
271
261
LT Borrowings
67
54
54
LT Finance Leases
891
966
959
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
600
600
600
Market Capitalization
6,582
11,222
8,824

Working Capital

EGP

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
1,962
2,371
2,717
Cash, Cash Equivalents & STI
861
984
1,294
Accounts Receivable, Net
570
703
753
Inventories
375
480
462
Total Current Liabilities
1,275
1,574
1,707
Payables & Accruals
- -
- -
- -
ST Debt
220
271
261
Deferred Revenue
- -
- -
- -

Growth Rates

EGP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.42%
12.07%
18.03%
Free Cash Flow
55.5%
52.58%
2.93%
Net Income, GAAP
37.43%
39.74%
17.15%
Sales/Revenue/Turnover
26.29%
31.22%
37.34%
Total Cash Common Dividend
- -
- -
1,851.58%

Quarterly Revenue

EGP

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,171
1,327
- -
- -
5,720
2025
1,583
1,960
- -
- -
7,855
2026
2,073
2,783
- -
- -
- -

Quarterly Earnings Per Share

EGP

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.7
0.19
- -
- -
1.82
2025
0.42
0.53
- -
- -
2.17
2026
0.75
0.66
- -
- -
- -

Quarterly Dividends Per Share

EGP

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.05
2025
- -
- -
- -
- -
0.92
2026
- -
- -
- -
- -
- -

Company Description

CEO
Hend El Sherbini
Full Time Employees
7,137
Sector
Health services
Industry
Hospital/Nursing management
Address
12 Castle Street Smart Village GZ Egypt JE2 3RT
IPO Date
May 6, 2015
Business
Integrated Diagnostics Holdings plc (IDH) is a leading woman-led consumer healthcare company that provides fully integrated medical diagnostic services across the Middle East and Africa. The company offers over 3,000 pathology tests encompassing immunology, microbiology, haematology, endocrinology, clinical chemistry, molecular biology, histopathology, cytogenetics, and genetics testing; radiology services including basic imaging, nuclear medicine, ultrasound, and radiotherapy; and molecular diagnostics for conditions such as hepatitis and diabetes glucose testing, delivered through its hub-spoke-spike model with over 600 branches. IDH operates core brands Al Borg and Al Borg Scan in Egypt, Al Mokhtabar in Egypt and Sudan, Biolab in Jordan and Saudi Arabia, Ultralab in Sudan, and Echo-Lab in Nigeria, primarily serving walk-in patients and contract segments with a focus on underserved markets. Founded in 2008 through the acquisition of Al Borg Laboratories (established 1990) and headquartered in Cairo, Egypt, IDH generates the majority of its revenue from Egypt while expanding regionally. Recent developments include the full acquisition of Biolab KSA in December 2024 by purchasing the remaining 49% stake for USD 3.2 million, bringing its ownership to 100%; the June 2025 acquisition of Cairo Ray for Radiotherapy by Al Borg, enhancing its Egyptian radiology portfolio; delisting from the Egyptian Exchange in 2024 to streamline operations on the London Stock Exchange; and strong financial performance with EGP 5.7 billion in 2024 revenue and 42% growth in first-half 2025.

Company News

  • Integrated Diagnostics Holdings plc (IDGXF) Q2 2026 Earnings Call Transcript

  • Integrated Diagnostics Holdings plc (IDGXF) Q1 2026 Earnings Call Transcript

  • Integrated Diagnostics Holdings plc (IDGXF) Q4 2025 Earnings Call Transcript

  • Integrated Diagnostics Holdings plc (IDGXF) Q3 2025 Earnings Call Transcript